Skip to main content

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) on Promising Path to Address Unmet ASD Needs

PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on developing novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. “While ASD is not uncommon, there are no pharmaceutical treatments approved to treat the disorder, only to manage the symptoms – which creates an unmet need in the industry… PaxMedica is on a mission to help, reduce and modulate some of the more challenging aspects of ASD. The company hopes to enable people with autism to integrate their behavior with others more successfully and improve their quality of life,” a recent article reads. The company recently released a Fireside Chat video with its Chairman and CEO Howard Weisman in which Weisman shared important updates and achievements in the company’s pipeline, including ASD, underscoring the commitment to groundbreaking therapies and transformative solutions. “PaxMedica plans to continue into 2024 with the momentum it has gained… The company is on a promising path to address the unmet medical needs associated with ASD, bringing hope to millions.”

To view the full article, visit https://ibn.fm/xxYhG

About PaxMedica Inc.

PaxMedica is a forward-looking clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (“APT”) aimed at addressing a range of challenging neurologic disorders, including autism spectrum disorder (“ASD”) and human African trypanosomiasis (“HAT”). Its portfolio encompasses critical areas within the neurology field, with a focus on pioneering advancements in both ASD and HAT treatments. The company is dedicated to the continuous development and evaluation of its pioneering program, PAX-101-an intravenous suramin formulation that lies at the heart of its efforts, particularly focused on innovative ASD and HAT treatment solutions. PaxMedica’s ongoing research initiatives not only prioritize the needs of ASD and HAT patients but also extend to exploring potential therapeutic applications for related conditions. For more information about the company, visit www.PaxMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.